Bioaffinity Technologies, INC 8-K filings

BioAffinity Technologies announced strong second quarter 2026 results, with CyPath Lung test volume surging 216% year-over-year and revenue increasing 19%, while advancing its diagnostic and therapeutic pipeline.

bioAffinity Technologies received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement, potentially leading to delisting.

bioAffinity Technologies announced the publication of a clinical review and white paper by its Chief Medical Officer, detailing a framework for integrating CyPath Lung into pulmonary nodule evaluation and cancer surveillance.

bioAffinity Technologies and Pictor, Inc. are collaborating to develop and commercialize next-generation diagnostic tests for asthma and COPD, aiming to improve personalized treatment through advanced proteomic analysis.

bioAffinity Technologies announced over 200% year-over-year sales growth for its CyPath Lung diagnostic in Q2 2026, driven by increased physician adoption and repeat utilization.

bioAffinity Technologies reports significant sales growth for its CyPath Lung test, announces a collaboration with Philips for veteran lung screening, and details progress in its companion diagnostics and skin cancer research.

BioAffinity Technologies has successfully closed a public offering, raising approximately $3.2 million to fund working capital and general corporate purposes.

bioAffinity Technologies announced a webinar on July 21, 2026, featuring clinical experts discussing emerging approaches to lung health screening and early detection for veterans.

bioAffinity Technologies announced a Society for Advanced Bronchoscopy webinar to discuss the expanding role of its noninvasive CyPath Lung test in early-stage lung cancer detection and management.

bioAffinity Technologies announced a patent allowance in Mexico for its CyPath Lung technology, enhancing its global intellectual property for early-stage lung cancer detection.

bioAffinity Technologies announced record monthly unit sales for its CyPath Lung diagnostic test in April 2026, with a nearly 300% increase compared to the previous year.

BioAffinity Technologies reports a 146% year-over-year increase in CyPath Lung unit sales for Q1 2026, alongside a strategic revenue shift towards higher-margin services.

bioAffinity Technologies stockholders approved a significant increase in equity incentive shares and authorized a potential reverse stock split.

bioAffinity Technologies released a case study demonstrating how its CyPath Lung test helped a physician correctly identify a pulmonary nodule as inflammation, avoiding an unnecessary biopsy.

bioAffinity Technologies announced its CyPath Lung diagnostic test will be featured at the prestigious Cleveland Clinic symposium on April 16, 2026.

bioAffinity Technologies announced its CyPath Lung diagnostic unit sales grew 146% year-over-year in Q1 2026, exceeding internal projections.

BioAffinity Technologies, Inc. has made new presentation materials available on its website for investor and operational updates.

bioAffinity Technologies announced it will host a virtual physician roundtable to discuss the clinical integration and utility of its noninvasive CyPath Lung diagnostic test for early lung cancer detection.

bioAffinity Technologies announced a new clinical case study demonstrating CyPath Lung's ability to provide actionable results and help patients avoid invasive procedures.

BioAffinity Technologies announced record 2025 revenue and unit sales for its flagship lung cancer diagnostic, CyPath Lung, alongside a strategic streamlining of its laboratory business.

Robert Anderson and Roby Joyce will not stand for re-election to the bioAffinity Technologies, Inc. Board of Directors at the upcoming 2026 Annual Meeting.

bioAffinity Technologies announced a new study with Brooke Army Medical Center to validate the use of CyPath Lung with deep suction sputum samples for early lung cancer detection.

bioAffinity Technologies' CyPath Lung test successfully guided a non-invasive surveillance strategy for an elderly patient with a suspicious lung nodule, avoiding an unnecessary biopsy.

BioAffinity Technologies, Inc. announced the posting of new investor presentation materials to its website for future management presentations.

BioAffinity Technologies announced the appointment of three nationally recognized pulmonary and lung cancer authorities to its Medical and Scientific Advisory Board to guide strategic priorities and CyPath Lung adoption.

BioAffinity Technologies, Inc. announced its 2026 Annual Meeting for April 30, 2026, and set a February 14, 2026, deadline for shareholder proposals.

BioAffinity Technologies' subsidiary, Precision Pathology Laboratory Services, successfully maintained its College of American Pathologists accreditation, reinforcing quality for its CyPath Lung test.

BioAffinity Technologies' subsidiary, Precision Pathology Laboratory Services, announces the transfer of 100% equity interest in Village Oaks Pathology Services from Dr. Roby P. Joyce to Dr. James Humphreys.

BioAffinity Technologies, Inc. adjourned its special stockholder meeting due to a lack of quorum, rescheduling it for January 19, 2026.

bioAffinity Technologies announced its CyPath Lung test successfully identified early-stage lung cancer in challenging cases, to be presented at the American Cancer Society National Lung Cancer Roundtable.